AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00054418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate sodium
Description: risedronate 35 mg weekly administered orally
Study NCT00054418 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet weekly administered orally for one year
Study NCT03551184 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Endotoxin
Description: Endotoxin at 0.6 ng/kg of body weight administered intravenously (Escherichia Coli, Lot nr G3E0609, United States Pharmacopeia Rockville, MD)
Study NCT03551184 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline administered intravenously
Study NCT04563572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PPG Smartwatch
Description: Participants will then receive a PPG sensor in form of a smartwatch) model and will be instructed to wear them continuously for 48 hours. Simultaneously, a 48-hour Holter ECG will be performed. Start time on the PPG-sensor and the Holter ECG will be matched and continuous heart rhythm and -rate monitoring will be initiated. Patients will wear the devices over a 48-hour period of time.
Study NCT01007097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
Study NCT01007097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 50 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
Study NCT01007097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 100 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
Study NCT01007097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 200 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
Study NCT01007097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: TAK-875 placebo-matching tablets and Glimepiride 2 mg or 4mg, capsules, orally, once daily for up to 12 weeks.
Study NCT01007097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-875 placebo-matching tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
Study NCT02395289 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Based Compassion Training (CBCT)
Description: Cognitive-Based Compassion Training (CBCT) is composed of secular, didactic instruction and meditation practices. CBCT includes the meditative practices of developing one-pointed concentration and mindfulness. CBCT will be one class per week, 2 hours each, for 8 weeks, for a total of 16 hours during the study. Each meditation class will include a didactic and discussion session that will describe the meditative technique introduced during the week and a practice meditation session. The training protocol is highly iterative and techniques introduced early in training are practiced daily. All participants will be asked to meditate approximately 30 minutes a day at home and will be given a meditation diary to record amount of time spent meditating per week.
Study NCT02395289 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health discussion
Description: Health discussion therapy is one class per week, 2 hours each, for 8 weeks. Each class will use interactive teaching methods to present the health material in an engaging and relevant manner. Representative weekly topics that will be covered include healthy diet, the role of exercise in emotional health, and the importance of sleep and relaxation. It is important to note that the material presented in the health discussion group, although intended to be beneficial to participants, does not include a contemplative component and is not iterative in nature.
Study NCT00092391 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live
Description: 0.5 mL subcutaneous injection of one of three sub-lots on Day 0
Study NCT00092391 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live
Description: 0.5 mL subcutaneous injection of one of three sub-lots on Day 0
Study NCT00092391 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)
Description: 0.5 mL subcutaneous injection on Day 0
Study NCT00092391 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)
Description: 0.5 mL subcutaneous injection on Day 0
Study NCT03562624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY98-7443
Description: Active ingredient content (in mg IND/LNG):~low dose 6.5 / 13.5; middle dose 12.5 / 13.5; high dose 15.4 / 13.5
Study NCT03562624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonogestrel (Skyla, BAY86-5028)
Description: Comparative LNG dose
Study NCT01332695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST101
Description: tablets for oral administration
Study NCT01332695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to match
Study NCT01574417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: control margarine
Description: Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the control margarine is consumed together with a high-fat milkshake.~Daily consumption of 20 gram of a control margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks.
Study NCT01574417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: plant stanol-enriched margarine
Description: Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the plant stanol-enriched margarine is consumed together with a high-fat milkshake.~Daily consumption of 20 gram of a plant stanol-enriched margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks.
Study NCT04565236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1
Description: 25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day according to individual requirements for 6 months.~The dose decisions are at the discretion of the investigator.
Study NCT04565236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2
Description: 12 year-old: 25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day for 6 months.~>12 year-old: 20 to 40 IU of Kovaltry per kg of body weight given via intravenous (IV) infusion two or three times per week for 6 months.~The dose decisions are at the discretion of the investigator.
Study NCT04565236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 3
Description: 15 to 50 IU of Kovaltry per kg body weight (minimum dose: 250 IU) given via intravenous (IV) infusions at least once a week.~The dose decisions are at the discretion of the investigator.
Study NCT02122055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl 0.7-1μg/kg，prn pain assessment is done every 4 hours，maintain Behavioral Pain Scale（BPS） 0-2.
Study NCT02122055 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sedation assessment
Description: Sedation assessment is done every 4 hours,maintain the Riker Sedation Agitation Score(SAS) 3-4.
Study NCT02122055 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Screen of weaning
Description: 1. Screen of weaning is done at 8:00 every morning. 2 If the patient is successful to wean, stop the Dexmedetomidine sedation. 3. If failed to wean, the patient is ventilated again and try to wean after 24 hours, until it is successful to wean and stop sedation，
Study NCT02122055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol is started with dosage of 0.3 mg/kg/h, observe the patient's response, increase 0.3 mg/kg/h propofol every 10 minutes until target sedation level is obtained(Riker Sedation Agitation Score(SAS) 3-4),then 0.3-3 mg/kg/h propofol is maintained.
Study NCT02122055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 2 mg is slowly titrated to Riker Sedation Agitation Score(SAS) 3-4 every 10 minutes, then Midazolam 0.02-0.1 mg/kg/h is maintained.
Study NCT02122055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: After the screen of the weaning is passed, change to Dexmedetomidine sedation, the dose is 0.2-0.7 mg/kg/h and continuously pumped, increase the dose 0.1-0.2 mg/kg/h every 30 minutes, titrate to Riker Sedation Agitation Score(SAS) 3-4，the maximum dose is 1 mg/kg/h maintained，and prepare for weaning.
Study NCT03154294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel will be diluted prior to infusion in 0.9% Sodium Chloride for Injection, USP; 5% Dextrose Injection, USP; 5% Dextrose and 0.9% Sodium Chloride Injection, USP; or 5% Dextrose in Ringer's Injection to a final concentration of 0.3 to 1.2mg/mL. At ambient temperature (approximately 25°C) and room lighting conditions the solution is physically and chemically stable for up to 27 hours. The diluted product will be prepared and stored in glass, polypropylene, or polyolefin containers; DEHP-containing (polyvinyl chloride (PCV)) containers should not be used. Paclitaxel will be administered using a vented Paclitaxel set with in-line 0.22-micron filter and run over 1 hour.
Study NCT03154294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-228
Description: TAK-228 will be provided in 30-ct, 60-cc high density polyethylene (HDPE) bottles with polypropylene, child-resistant caps and induction seal. TAK-228 will be administered on an empty stomach. It is recommended that each dose of TAK-228 + TAK-117 be given PO with 8 ounces (240 mL) of water. Patients should be instructed to refrain from eating and drinking (except for water and prescribed medications) for 2 hours before and 1 hour after each dose.
Study NCT03154294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-117
Description: TAK-117 will be provided in 30-ct, 60-cc high density polyethylene (HDPE) bottles with polypropylene, child-resistant caps and induction seal. TAK-117 will be administered on an empty stomach. It is recommended that each dose of TAK-228 + TAK-117 be given PO with 8 ounces (240 mL) of water. Patients should be instructed to refrain from eating and drinking (except for water and prescribed medications) for 2 hours before and 1 hour after each dose.
Study NCT03105661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol Hydrochloride 200 mg
Description: Anti-hypertensive prescribed for increased cardiac output as determined by Impedance Cardiography
Study NCT03105661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NIFEdipine 60 mg
Description: Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by Impedance Cardiography
Study NCT03105661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol 25 mg
Description: Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater
Study NCT01117805 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone counseling intervention
Description: self-regulation telephone counseling program for African American women with asthma
Study NCT02352649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neovasculgen
Study NCT02347462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilevel Positive Airway Pressure (BiPAP) (Trilogy BiPAP, Philips Respironics)
Description: Children in the intervention group will receive BiPAP (Trilogy, Philips Respironics; spontaneous trigger mode) via a nasal or full face mask. End expiratory positive airway pressure (EPAP) will be set at 5cm H20. Inspiratory positive airway pressure (IPAP) will be titrated to achieve a tidal volume of 6 - 9 ml/kg. These settings will remain unchanged throughout the study period.
Study NCT02347462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard care according to the hospital severe asthma protocol
Study NCT02347462 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care according to the hospital severe asthma protocol
Study NCT03250624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD5024 0.3% cream
Description: Participants applied CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 milligrams per centimeter square (mg/cm\^2) once daily for 6 weeks.
Study NCT03250624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants applied placebo matched to CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 mg/cm\^2 once daily for 6 weeks.
Study NCT01894555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 81 mg daily for 4 weeks
Study NCT01235338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDX + Venlafaxine XR
Description: * Day 1-5 LDX 30mg~* Day 6-10 LDX 50mg~* Day 11-15 LDX 70mg~* Day 16-20 LDX 70mg and Venlafaxine XR 75mg daily~* Day 21-25 LDX 70mg and Venlafaxine XR 150mg daily~* Day 26-30 LDX 70mg and Venlafaxine XR 225mg daily~* Day 31-34 Venlafaxine XR 150mg daily~* Day 35-38 Venlafaxine XR 75mg daily.
Study NCT01235338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR + LDX
Description: * Day 1-5 Venlafaxine XR 75mg~* Day 6-10 Venlafaxine XR 150mg~* Day 11-15 Venlafaxine XR 225mg~* Day 16-20 Venlafaxine XR 225mg and LDX 30mg daily~* Day 21-25 Venlafaxine XR and LDX 50mg daily~* Day 26-30 Venlafaxine XR 225mg and LDX 70mg daily~* Day 31-34 Venlafaxine XR 150mg~* Day 35-38 Venlafaxine XR 75mg.
Study NCT01844791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCZ103-OS
Description: OCZ103-OS is given in combination with chemotherapy each cycle
Study NCT01844791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum
Description: Platinum is given as standard chemotherapy each cycle
Study NCT01844791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is given as standard chemotherapy each cycle
Study NCT02509611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Description: Yoga programs that were used in previous PD studies will be incorporated into the design of the proposed intervention program. Two yoga experts who are specialized in musculoskeletal/neurological disorders will review the program. The yoga intervention classes will be taught by a Registered Yoga Teacher. The 60 minute long yoga session will be held twice a week for 12 weeks at a community center in St. Louis Park.
Study NCT02509611 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hatha yoga
Description: Yoga programs that were used in previous PD studies will be incorporated into the design of the proposed intervention program. Two yoga experts who are specialized in musculoskeletal/neurological disorders will review the program. The yoga intervention classes will be taught by a Registered Yoga Teacher. The 60 minute long yoga session will be held twice a week for 12 weeks at a community center in St. Louis Park.
Study NCT00948428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imiquimod
Description: 5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
Study NCT00948428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aldara™
Description: 5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
Study NCT00948428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Topical cream vehicle matching Generic imiquimod dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
Study NCT03425851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diapers
Description: Receive 600 diapers.
Study NCT03425851 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resources of diaper banks
Description: Caregivers will receive resources of diaper banks.
Study NCT04483128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation: Interferential Current (IFC): Experimental Group
Description: Application of IFC with Sonopuls 692® (Enraf-Nonius BV, Rotterdam, The Netherlands) device. Parameters:~1. Carrier frequency of 4000 Hz~2. Amplitude modulated frequency of 65 Hz (AMF)~3. Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.~4. Intensity will depend on subjet's tolerance but without generate visible muscle twitches.~5. Session duration: 25 minutes
Study NCT04483128 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electrical stimulation: Interferential Current (IFC): Control Group
Description: Application of IFC with Sonopuls 692® (Enraf-Nonius BV, Rotterdam, The Netherlands) device. Parameters:~1. Carrier frequency of 4000 Hz~2. Amplitude modulated frequency of 65 Hz (AMF)~3. Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.~4. NO intensity (0 mA)~5. Session duration: 25 minutes
Study NCT02493335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 0.5mg orodispersible tablet twice daily
Study NCT02493335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 1mg orodispersible tablet twice daily
Study NCT02493335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo orodispersible tablet twice daily
Study NCT01783470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beta3-adrenergic receptor agonist
Description: single dose. The subjects were randomized to receive placebo on one study day and active beta3-adrenergic receptor agonist on the other study day.
Study NCT00766064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Paliperidone will be gradually increased to a final dose between 3 - 6 mg/day according to the following schedule:~Weeks 1 - 3: 3 mg daily, Weeks 4 - 5: flexible dosing according clinical situation, dose range between 3 mg - 6 mg daily\*, Week 6: fixed dose,~\*Criteria to increase the dose from 3 mg to 6 mg daily are 1\] absence of any side effects, 2\] patients not showing a sufficient response to 3 mg paliperidone can be increased to 6 mg daily. Response is defined as change in depression and anxiety ratings of at least 30% compared to baseline.
Study NCT01237301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM Group
Description: Using CGM unblinded for 16 weeks versus fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes.
Study NCT01237301 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SMBG Group
Description: Fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes. Used CGM blinded once every four weeks.
Study NCT00093470 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Clinical Observation
Description: Undergo observation
Study NCT00093470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Given PO
Study NCT03367611 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Immunochemical faecal occult blood test (iFOBT)
Description: All participants in the study will collect a single faecal sample for haemoglobin measurement.
Study NCT00033592 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00033592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion hydrochloride
Study NCT00033592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine
Study NCT01606007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: Tablets, Oral, 5mg , Once daily, 24 weeks
Study NCT02168712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate continuous exercise training
Study NCT02168712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval exercise training
Study NCT01606007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 5mg , Once daily, 24 weeks
Study NCT01606007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR
Description: Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks
Study NCT01770145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APOKYN
Description: Apokyn will be titrated to an optimum dose which reproduces 90% of the subjects' best on UPDRS score during the Initiation Period. During the APOKYN Treatment Period, subjects will inject the dose identified in the initiation period once daily at the time of their normal scheduled L-Dopa dose (L-Dopa will be delayed by 40 minutes).
Study NCT01770145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-dopa
Description: Subjects on a stable L-Dopa regimen will be entered into the study. For the L-Dopa Baseline Period through the Initiation Period, subjects will continue their normal L-Dopa dosing regimen. During the APOKYN Treatment Period, subjects will replace their normally scheduled first morning L-Dopa dose with an APOKYN injection, and then administer their normal first morning L-Dopa dose 40 minutes later.